The Biden administration on Thursday asserted its authority to seize the patents of certain costly medications in a new push to slash high drug prices and promote more pharmaceutical competition.

The administration unveiled a framework outlining the factors federal agencies should consider in deciding whether to use a controversial policy, known as march-in rights, to break the patents of drugs that were developed with federal funds but are not widely accessible to the public. For the first time, officials can now factor in a medication’s price — a change that could have big implications for drugmakers depending on how the government uses the powers.

“When drug companies won’t sell taxpayer-funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard said during a call with reporters Wednesday.

  • RainfallSonata@lemmy.world
    link
    fedilink
    arrow-up
    5
    arrow-down
    11
    ·
    11 months ago

    Non neolib? Introducing competition rather than seizing and making them public is about as neolib as you can get.

    • agent_flounder@lemmy.world
      link
      fedilink
      English
      arrow-up
      12
      arrow-down
      1
      ·
      11 months ago

      So by letting a company keep their monopoly due to federally subsidized patent thus harming citizens but helping the company is… less neolib?

      Whatever it is, it seems shittier than making a move to fuck a company – if it results in reduced drug prices anyway.

      • SCB@lemmy.world
        link
        fedilink
        arrow-up
        2
        arrow-down
        6
        ·
        11 months ago

        So by letting a company keep their monopoly due to federally subsidized patent thus harming citizens but helping the company is… less neolib?

        Yes. Monopolization is one of the many externalities that government exists to address within a neoliberal framework